CAS Number147859-80-1
SynonymsL-trans-Epoxysuccinyl-isoleucyl-proline methyl ester propylamide; L-TRANS-EPOXYSUCCINYL-ILE-PRO-OME PROPYLAMIDE; MFCD03452890; L-trans-Epoxysuccinic Ile-Pro-OMe Propylamide; (L-3-trans-(Propylcarbamyl)oxirane-2-carbonyl)-L-isoleucyl-L-proline methyl ester; CA-074-Me
Molecular FormulaC19H31N3O6
Molecular Weight397.46600
Purity98%
Appearancepowder
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 147859-80-1 |
| Catalog No. | 2A-1169010 |
| Chinese Name | CA-074甲酯 |
| Synonyms | L-trans-Epoxysuccinyl-isoleucyl-proline methyl ester propylamide; L-TRANS-EPOXYSUCCINYL-ILE-PRO-OME PROPYLAMIDE; MFCD03452890; L-trans-Epoxysuccinic Ile-Pro-OMe Propylamide; (L-3-trans-(Propylcarbamyl)oxirane-2-carbonyl)-L-isoleucyl-L-proline methyl ester; CA-074-Me |
| Molecular Formula | C19H31N3O6 |
| Molecular Weight | 397.46600 |
| Purity | 98 |
| Appearance | powder |
| Storage Condition | Storage method: -15 °C |
| Application | CA-074 methyl ester is a specific Cathepsin B inhibitor with various biological activities such as neuroprotection, anti-cancer, and anti-inflammatory. |
| PubChem ID | 11121579 |
| SMILES | CCCNC(=O)C1OC1C(=O)NC(C(=O)N1CCCC1C(=O)OC)C(C)CC |
| InChI | InChI=1S/C19H31N3O6/c1-5-9-20-16(23)14-15(28-14)17(24)21-13(11(3)6-2)18(25)22-10-7-8-12(22)19(26)27-4/h11-15H,5-10H2,1-4H3,(H,20,23)(H,21,24)/t11-,12-,13-,14-,15-/m0/s1 |
| InChI Key | XGWSRLSPWIEMLQ-YTFOTSKYSA-N |
| Hazard Symbols | transportation |
| MSDS | msds/169090_2_147859_80_1.pdf |
| Bioactivity | CA-074 methyl ester is a specific inhibitor of Cathepsin B, which has potent bioactivities such as neuroprotective, anti-cancer, and anti-inflamatory effects. Related Catalog Signaling Pathways >> Metabolic Enzyme/Protease >> Cathepsin Research Areas >> Neurological Disease In Vitro CA-074Me (5 μM and 50 μM) inhibits RANKL-induced osteoclastogenesis in BMM cells derived from C57BL/6J and NOD/ShiLtJ mice. CA-074Me exerts its anti-osteoclastogenic effect within 24 hours post-RANKL stimulation in vitro. CA-074Me does not exert its anti-osteoclastogenic effect via the MAPK-ERK signaling cascade. CA-074Me inhibits c-FOS upregulation and subsequent NFATc1 autoamplification following RANKL stimulation.[2]. CA-074Me reduces apoptosis induced by CVB1[3]. In Vivo Hippocampal CA1 neuronal programmed necrosis induced by global cerebral I/R injury is prevented by CA074-me (1 μg, 10 μg) both pre-treatment and post-treatment. The rupture of lysosomal membrane and the leakage of cathepsin-B, and this is strongly inhibited by CA074-me pre-treatment. The overexpression and nuclear translocation of RIP3 and the reduction of NAD+ level after I/R injury are also inhibited, while the upregulation of Hsp70 is strengthened by CA074-me pre-treatment[1]. CA-074Me (30 mg/kg) is capable of inhibiting osteoclastogenesis and bone degradation in vivo[2]. In the CVB+CA-074Me (4 mg/kg/day i.m.) guinea pigs group, the scores of inflammation significantly decrease in comparison with the CVB+None group. In CVB+CA-074Me group, the number of CD8+T cells decrease in comparison with the sham group[3]. Kinase Assay After seven days of cell culture and osteoclast generation, the media is removed and washed three times with PBS. BMMs are fixed with a fixing solution supplied by the manufacturer. The cells are incubated at 37°C with a solution containing deionized water, Fast Garnet GBC, Napthol phosphate, Acetate, and Tartrate for 1 h. The staining solution is removed, washed with PBS (3×), and air-dried. TRAP positive cells with three or more nuclei across whole culture area are counted as multinucleated osteoclasts using light microscopy. Animal Admin RANKL (0.08 mg/kg) with and without CA-074Me (10 mg/kg or 30 mg/kg) are mixed in sterile, nonimmunogenic 1% Extracel-HP gel. The gel is composed of thiol-modified sodium hyaluronate, thiol-modified heparin, thiol-modified gelatin, and degassed deionized sterile water. The hydrogel mixture is prepared in an aseptic hood using a sterile syringe. The control sham hydrogel contained sterile Phosphate Buffered Saline (PBS) without any cytokines. The osteolysis group is given 0.08 mg/kg RANKL in a hydrogel to induce pathologic bone loss. The hydrogel-only, hydrogel-RANKL, and hydrogel-RANKL-CA-074Me mixture is injected into 8-week old male mice calvarium in an aseptic hood (n = 5) following general anesthesia (80 mg/kg of ketamine and 7 mg/kg of xylazine). After four days, the calvaria are excised, fixed in 4% formaldehyde for 24 h, decalcified in 20% EDTA for one week, and sectioned into slides from paraffin blocks. The slides undergo Tartrate-Resistant Acid Phosphatase (TRAP) staining to identify osteoclasts. References [1]. Xu Y, et al. Protective mechanisms of CA074-me (other than cathepsin-B inhibition) against programmed necrosis induced by global cerebral ischemia/reperfusion injury in rats. Brain Res Bull. 2016 Jan;120:97-105. [2]. Patel N, et al. CA-074Me compound inhibits osteoclastogenesis via suppression of the NFATc1 and c-FOS signaling pathways. J Orthop Res. 2015 Oct;33(10):1474-86. [3]. Zhang L, et al. Treatment with CA-074Me, a Cathepsin B inhibitor, reduces lung interstitial inflammation and fibrosis in a rat model of polymyositis. Lab Invest. 2015 Jan;95(1):65-77. Chemical & Physical Properties Molecular Formula C19H31N3O6 Molecular Weight 397.46600 Exact Mass 397.22100 PSA 117.34000 LogP 0.69460 InChIKey XGWSRLSPWIEMLQ-YTFOTSKYSA-N SMILES CCCNC(=O)C1OC1C(=O)NC(C(=O)N1CCCC1C(=O)OC)C(C)CC Storage condition -20℃ |
| Use of | Properties Synonym More Synonyms Related Catalog Signaling Pathways >> Metabolic Enzyme/Protease >> Cathepsin Research Areas >> Neurological Disease In Vitro CA-074Me (5 μM and 50 μM) inhibits RANKL-induced osteoclastogenesis in BMM cells derived from C57BL/6J and NOD/ShiLtJ mice. CA-074Me exerts its anti-osteoclastogenic effect within 24 hours post-RANKL stimulation in vitro. CA-074Me does not exert its anti-osteoclastogenic effect via the MAPK-ERK signaling cascade. CA-074Me inhibits c-FOS upregulation and subsequent NFATc1 autoamplification following RANKL stimulation.[2]. CA-074Me reduces apoptosis induced by CVB1[3]. References [1]. Xu Y, et al. Protective mechanisms of CA074-me (other than cathepsin-B inhibition) against programmed necrosis induced by global cerebral ischemia/reperfusion injury in rats. Brain Res Bull. 2016 Jan;120:97-105. [2]. Patel N, et al. CA-074Me compound inhibits osteoclastogenesis via suppression of the NFATc1 and c-FOS signaling pathways. J Orthop Res. 2015 Oct;33(10):1474-86. [3]. Zhang L, et al. Treatment with CA-074Me, a Cathepsin B inhibitor, reduces lung interstitial inflammation and fibrosis in a rat model of polymyositis. Lab Invest. 2015 Jan;95(1):65-77. Chemical & Physical Properties Molecular Formula C19H31N3O6 Exact Mass 397.22100 PSA 117.34000 LogP 0.69460 InChIKey XGWSRLSPWIEMLQ-YTFOTSKYSA-N Storage condition -20℃ |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| Zopiclone N-Oxide | 43200-96-0 | 2A-1169000 |
| S)-2-(((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methyl)aMino)-3- Methylbutanoic acid | 676129-92-3 | 2A-1169003 |
| CYS-GLY; L-Cysteinylglycine | 19246-18-5 | 2A-1169004 |
| Calendula PE | 2A-0169007 | 2A-1169007 |
| 9-fluoro-11beta,16alpha,17,21-tetrahydroxypregn-4-ene-3,20-dione | 337-02-0 | 2A-1169009 |
| PR 957(ONX 0914) | 960374-59-8 | 2A-1169011 |
| 1-(4-hydroxy-3-methoxyphenyl)decan-5-one | 27113-22-0 | 2A-1169012 |
| D-Glucose-6-Phosphate Barium Salt | 58823-95-3 | 2A-1169016 |
| NE-CARBOXYMETHYL-L-LYSINE | 5746-04-3 | 2A-1169018 |
| germacreneB,1,5-dimethyl-8-(1-methylethylidene)-1,5-cyclodecadiene | 15423-57-1 | 2A-1169021 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS